Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.

Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL.

J Clin Pharmacol. 2007 Apr;47(4):430-44.

PMID:
17389552
[PubMed - indexed for MEDLINE]
2.

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M.

Lancet. 2008 Aug 30;372(9640):719-27. doi: 10.1016/S0140-6736(08)61168-X. Epub 2008 Aug 20.

PMID:
18722008
[PubMed - indexed for MEDLINE]
3.

PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.

Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2064-9. doi: 10.1073/pnas.0711795105. Epub 2008 Feb 6.

PMID:
18272502
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.

van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P.

Int J Clin Pharmacol Ther. 2004 Oct;42(10):534-42.

PMID:
15516022
[PubMed - indexed for MEDLINE]
5.

Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.

Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC.

Int J Clin Pharmacol Ther. 2002 May;40(5):198-206.

PMID:
12051571
[PubMed - indexed for MEDLINE]
6.

Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.

Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, Sharma SK, Cross MR, Dutt C.

Clin Drug Investig. 2009;29(9):559-75. doi: 10.2165/11315260-000000000-00000.

PMID:
19663519
[PubMed - indexed for MEDLINE]
7.

Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.

Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL.

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1262-72. doi: 10.1164/rccm.201001-0137OC. Epub 2010 Jul 9.

PMID:
20622033
[PubMed - indexed for MEDLINE]
8.

Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.

Vaughan D, Speed J, Medve R, Andrews JS.

Clin Ther. 2010 Jan;32(1):146-60. doi: 10.1016/j.clinthera.2010.01.006.

PMID:
20171420
[PubMed - indexed for MEDLINE]
9.

Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.

Moore KH, Hussey EK, Shaw S, Fuseau E, Duquesnoy C, Pakes GE.

Cephalalgia. 1997 Jun;17(4):541-50.

PMID:
9209776
[PubMed - indexed for MEDLINE]
10.

Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

Zhu Y, Statkevich P, Cutler DL.

Int J Clin Pharmacol Ther. 2007 Oct;45(10):539-47.

PMID:
17966839
[PubMed - indexed for MEDLINE]
11.

Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.

Kunka RL, Hussey EK, Shaw S, Warner P, Aubert B, Richard I, Fowler PA, Pakes GE.

Cephalalgia. 1997 Jun;17(4):532-40.

PMID:
9209775
[PubMed - indexed for MEDLINE]
12.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
[PubMed - indexed for MEDLINE]
13.

Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.

Tarral A, Dostert P, Guillevic Y, Fabbri L, Rondelli I, Mariotti F, Imbimbo BP.

J Clin Pharmacol. 2003 Aug;43(8):901-11.

PMID:
12953347
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.

Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.

Clin Ther. 2008 Oct;30(10):1817-30. doi: 10.1016/j.clinthera.2008.10.013.

PMID:
19014837
[PubMed - indexed for MEDLINE]
15.

Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.

Vollmer T, Blight AR, Henney HR 3rd.

Clin Ther. 2009 Oct;31(10):2215-23. doi: 10.1016/j.clinthera.2009.10.007.

PMID:
19922892
[PubMed - indexed for MEDLINE]
16.

Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.

Pieniaszek HJ Jr, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM.

J Clin Pharmacol. 2002 Jul;42(7):738-53.

PMID:
12092741
[PubMed - indexed for MEDLINE]
17.

Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.

van Marle S, van Vliet A, Sollie F, Kambayashi Y, Yamada-Sawada T.

Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.

PMID:
15968885
[PubMed - indexed for MEDLINE]
18.

Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.

Moore KH, Cass LM, Dallow N, Hardman TC, Jones A, Boyce M, Prince WT.

Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):805-11.

PMID:
11294370
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study.

Chu NN, Chen WL, Xu HR, Li XN.

Clin Drug Investig. 2009;29(7):451-7. doi: 10.2165/00044011-200929070-00003.

PMID:
19499962
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.

Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA.

Clin Pharmacol Ther. 2005 Dec;78(6):675-88.

PMID:
16338283
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk